Skip to Content

Investors

Company Profile

Altimmune is a clinical stage immunotherapeutics biotechnology company located in Montgomery County, MD with an additional operating site in London, UK. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec and Densigen, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.

Documents and Files
Corporate Governance and Nominating Committee
Code of Business Conduct and Ethics
Corporate Governance Guidelines
Maryland Tech Council Announces Finalists for 29th Annual Industry Awards
Source
Maryland Tech Council
Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger
Source
Benzinga
Altimmune nabs $120.2 million federal contract for nasal spray anthrax vaccine
Source
Washington Business Journal
Altimmune wins $120M BARDA contract to advance nasal spray anthrax vaccine
Source
FiercePharma
BARDA awards Altimmune anthrax contract
Source
BioCentury
Vaxin changes name to Altimmune
Source
BioPrepWatch
Vaxin moves from Birmingham to Maryland
Source
Birmingham News

Company Profile

Altimmune is a clinical stage immunotherapeutics biotechnology company located in Montgomery County, MD with an additional operating site in London, UK. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.

Featured Video

 

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC
Email: arr@lifesciadvisors.com

View all

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Learn more